Author

E. Makela

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

E. Loyttyniemi· 2 shared J. Westermarck· 2 shared M. Itala-Remes· 2 shared T. Varila· 2 shared U. Salmenniemi· 2 shared C. Lucas· 1 shared K. Pavic· 1 shared O. Kauko· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Loyttyniemi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias

E. Makela, K. Pavic, T. Varila, U. Salmenniemi, E. Loyttyniemi, S. Nagelli, V.-M. Kahari, R. E. Clark, V. K. Bachanaboyina, C. Lucas, M. Itala-Remes, J. Westermarck

The paper discovers a novel CIP2A splicing variant, NOCIVA, which is overexpressed in myeloid leukemias and correlates with poor clinical outcomes.

bioRxiv · Aug 24, 2020Cancer Biology

ARPP19 promotes MYC expression and associates with patient relapse in acute myeloid leukemia

E. Makela, E. Loyttyniemi, U. Salmenniemi, O. Kauko, T. Varila, V. Kairisto, M. Itala-Remes, J. Westermarck

This study identifies ARPP19 as an oncogenic PP2A inhibitor in AML that predicts relapse independently of risk classification and is associated with disease activity.

bioRxiv · Jul 5, 2019Cancer Biology